Published in AIDS Weekly, November 17th, 1997
Interim analysis of Pediatric AIDS Clinical Trials Groups (PACTG) Trial 338 included data from 162 of 298 children aged 2 to 17 years who received either zidovudine (AZT) plus lamivudine (3TC), stavudine (d4T) plus ritonavir, or AZT plus 3TC plus ritonavir.
Significantly more children in the ritonavir-containing regimens achieved an undetectable plasma viral load (<400 copies/mL) than those in the AZT/3TC group.
"The first large study in children comparing protease-inhibitor-containing treatments...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.